Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX0G7E)

• Drug Name: [(125)I] RB129 Drug Info
• Synonyms: GLYCYRRHETINIC ACID; Uralenic acid; 18-beta-Glycyrrhetinic acid; Arthrodont; Glycyrrhetin; Jintan; Rhetinic Acid; 18beta-Glycyrrhetinic acid; Biosone; alpha-Glycyrrhetinic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolonum [INN-Latin]; Enoxolona [INN-Spanish]; UNII-P540XA09DR; Enoxolone [INN:BAN:DCF]; CCRIS 3962; EINECS 207-444-6; NSC 35347; 3-Glycyrrhetinic acid; BRN 2229654; Glycyrrhetinate; MLS000028748; CHEMBL230006; P540XA09DR; Glycyrrhetinic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMX0G7E

Molecule-Related Drug Atlas

Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG-7234	DM5RAB9	Type-2 diabetes	5A11	Phase 2	[4]
3-acetyl-11-keto-beta-boswellic acid	DMGO2D7	Discovery agent	N.A.	Investigative	[5]
11-keto-beta-boswellicacid	DMM6CJI	Discovery agent	N.A.	Investigative	[5]
Ganoderic acid A	DM42EVG	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLYCYRRHIZIN	DM8M2N3	Influenza virus infection	1E30-1E32	Phase 3	[6]
BVT.2733	DM6RUKX	Lupus	4A40	Phase 3	[7]
INCB13739	DMLQ3PO	Type-2 diabetes	5A11	Phase 2a	[8]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[5]
JTT-654	DM50M2R	Type-2 diabetes	5A11	Phase 2	[4]
RG-4929	DMT4QRD	Metabolic disorder	5C50-5D2Z	Phase 2	[4]
BMS-770767	DMTVGY7	Hypercholesterolaemia	5C80.0	Phase 2	[4]
UE-2343	DMIERPK	Alzheimer disease	8A20	Phase 2	[9]
AZD-4017	DML9M5S	Ocular hypertension	9C61.01	Phase 2	[4]
Xanamem	DM580GT	Alzheimer disease	8A20	Phase 1/2	[10]

Drug(s) Targeting Aminopeptidase N (ANPEP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IP10 C8	DMANRGW	Psoriasis vulgaris	EA90	Phase 2	[11]
KELATORPHAN	DMOX8FD	Discovery agent	N.A.	Investigative	[12]
(1-Amino-3-phenyl-propyl)-phosphinic acid	DMXD697	Discovery agent	N.A.	Investigative	[13]
N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide	DM5F04D	Discovery agent	N.A.	Investigative	[14]
N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide	DMTMDZ4	Discovery agent	N.A.	Investigative	[14]
N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide	DM1L89K	Discovery agent	N.A.	Investigative	[14]
1-aminohexylphosphonic acid	DMFUABI	Discovery agent	N.A.	Investigative	[15]
(S)-2-Amino-3-phenyl-propane-1-thiol	DMMAUKO	Discovery agent	N.A.	Investigative	[13]
(Amino-phenyl-methyl)-phosphinic acid	DMS4ZVK	Discovery agent	N.A.	Investigative	[13]
1-aminohexylphosphonic acid monophenyl ester	DML6UJM	Discovery agent	N.A.	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aminopeptidase N (ANPEP)	TTPHMWB	AMPN_HUMAN	Inhibitor	[2]
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	TTN7BL9	DHI1_HUMAN	Inhibitor	[1]
Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)	TT9H85R	DHI2_HUMAN	Inhibitor	[3]

References

• [1] Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, a... J Biol Chem. 2004 Apr 30;279(18):18415-24.
• [2] Ontogenic and adult whole body distribution of aminopeptidase N in rat investigated by in vitro autoradiography. Biochimie. 2004 Feb;86(2):105-13.
• [3] Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene. 2003 Mar 20;22(11):1663-7.
• [4] New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
• [5] 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
• [6] Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
• [7] Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
• [8] Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.
• [11] Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
• [12] Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. J Med Chem. 1988 Sep;31(9):1825-31.
• [13] Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6.
• [14] Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34.
• [15] New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6.